Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.

Antiviral research - 1 May 2010

Armstrong-James Darius, Stebbing Justin, Scourfield Andrew, Smit Erasmus, Ferns Bridget, Pillay Deenan, Nelson Mark

Abstract excerpt

Therapy for infection with HIV-2 remains limited. We report an HIV-2-infected patient in whom genotyping demonstrated PI, NRTI and NNRTI resistance, with a subsequent response to raltegravir- and maraviroc-based therapy. Further studies are required to assess the clinical efficacy of maraviroc in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Cyclohexanes
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to Pyrrolidinones

Share to Raltegravir Potassium

Share to Triazoles

Source

Identifiers

PMID: 20211653
DOI: 10.1016/j.antiviral.2010.02.324

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20211653-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.PMID 20211653Read ↗

Antiretroviral drug-resistant HIV-2 infection--a new therapeutic dilemma.Semantic proximity Read ↗

Raltegravir treatment response in an HIV-2 infected patient: a case reportSemantic proximity Read ↗

The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series.Semantic proximity Read ↗

Diagnosis, antiretroviral therapy, and emergence of resistance to antiretroviral agents in HIV-2 infection: a review.Semantic proximity Read ↗

In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.Semantic proximity Read ↗

Special Aspects of the Treatment of HIV-2-Infected PatientsSemantic proximity Read ↗

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.Semantic proximity Read ↗

Efficacy and safety of a salvage regimen based on tipranavir, enfuvirtide and three nucleoside analogues in HIV1 infected patients with clinical progression: 96-week evaluation.Semantic proximity Read ↗

Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients.Semantic proximity Read ↗

Dolutegravir for the treatment of HIV-2 infection.Semantic proximity Read ↗

Efficacy and safety of antiretroviral regimens including raltegravir to treat HIV-infected patients with hemophilia.Semantic proximity Read ↗

Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.